.Attributes Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ sophisticated breast cancer cells as well as energetic or even dependable mind metastases presented consistent intracranial activity and also wide spread efficiency of T-DXd.